Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J.
Zinzani PL, et al. Among authors: buccheri v.
Blood Adv. 2022 Jan 25;6(2):590-599. doi: 10.1182/bloodadvances.2021004970.
Blood Adv. 2022.
PMID: 34644372
Free PMC article.